Abstracts tagged "Kidney"

Abstract Number: 1921 • 2017 ACR/ARHP Annual Meeting
Urine Angiostatin and VCAM-1 Surpass Conventional Metrics in Predicting Elevated Renal Pathology Activity Indices in Lupus Nephritis
Samar Soliman^1,2, Fatma Mohamed³, Faten Ismail³, Ramesh Saxena⁴ and Chandra Mohan², ¹Rheumatology and rehabilitation, University of Minya, Minya, Egypt, ²Biomedical Engineering, University of Houston, Houston, TX, ³Rheumatology and Rehabilitation, University of Minya, Minya, Egypt, ⁴Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The goal of this study is to investigate how urinary angiostatin, VCAM-1 and established measures of renal function relate to specific histologic findings in…
Abstract Number: 2052 • 2017 ACR/ARHP Annual Meeting
Apply Musculoskeletal Ultrasonography to Predict Chronic Gouty Arthritis in Patients with Chronic Kidney Diseases
Zheng-Hao Huang¹, Chi-Ching Chang², En Chao³, Hui-Hsun Chiang⁴, Shu-Yi Lin⁵, Kun-Lin Wu⁶, Hsiang-Cheng Chen⁵, Shi-Jye Chu⁵, San-Yuan Kao⁵, Tsung-Yun Hou⁵, Feng-Cheng Liu⁵, Chen-Hung Chen⁷, Deh-Ming Chang⁸ and Chun-Chi Lu⁹, ¹Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital; Tri-service general hospital, National Defense Medical Center, Taipei, Taiwan, ²Taipei Medical University Hospital, Taipei, Taiwan, ³Tri-Service General Hospital Songshan Branch, Taipei, Taiwan, ⁴School of Nursing, National Defense Medical Center, Taipei, Taiwan, ⁵Tri-Service General Hospital, Taipei, Taiwan, ⁶Armed Forces Taoyuan General Hospital, Taipei, Taiwan, ⁷Taipei Tzu Chi hospital, Taipei, Taiwan, ⁸Taipei Veterans General Hospital, Taipei, Taiwan, ⁹University of Washington; Tri-Service General Hopsital, National Defense Medical Center, Seattle, WA
Background/Purpose: Gouty arthritis, caused by the deposition of monosodium urate (MSU) monohydrate crystals at joints, is comprised of multiple inflammatory processes in synovium, tendons, cartilages…
Abstract Number: 2399 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Have Lower Glomerular Filtration Rate Compared to Healthy Population: Role of Inflammation
Suad Hannawi¹ and Issa Al Salmi², ¹Rheumatology, Asst.Prof, Dubai, United Arab Emirates, ²Prof, Muscat, Oman
Background/Purpose: Rheumatoid Arthritis-(RA) is associated with subclinical kidney impairment which contributes to increase mortality and morbidity. The role of inflammation on kidney function in inflammatory…
Abstract Number: 2400 • 2017 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis: Vitamin-D Deficiency Is an Outcome and a Cause of Subclinical Renal Impairment
Suad Hannawi¹ and Issa Al Salmi², ¹Rheumatology, Asst.Prof, Dubai, United Arab Emirates, ²Prof, Muscat, Oman
Background/Purpose: Vitamin D deficiency is highly prevalent in patients with rheumatoid arthritis (RA), and it is linked to RA disease severity. Two steps of hydroxylation…
Abstract Number: 2401 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis with Kidney Dysfunction Contributes to Higher Risk of Cardiovascular Disease Development
Suad Hannawi¹ and Issa Al Salmi², ¹Rheumatology, Asst.Prof, Dubai, United Arab Emirates, ²Prof, Muscat, Oman
Background/Purpose: Reduced kidney function render patients with RA rheumatoid arthritis (RA), have an increased risk of cardtiovascular disease (CVD), particulary ischemic heart disease (IHD). This…
Abstract Number: 2846 • 2017 ACR/ARHP Annual Meeting
Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Renal-Related and Decreased Risk of Dementia-Related Death
Ana Beatriz Vargas-Santos¹, Tuhina Neogi², Geraldo Castelar-Pinheiro¹ and Aleksandra Turkiewicz³, ¹Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden
Background/Purpose: There is recognized higher mortality among gout patients, with cardiovascular (CV) mortality having been previously reported. The present study aimed to examine cause-specific mortality…
Abstract Number: 322 • 2017 ACR/ARHP Annual Meeting
Safety of Denosumab in a Monocentric Cohort of Kidney Transplant Recipients
Sonia Doddoli, Pierre Lafforgue and Thao Pham, Rheumatology, APHM, Aix Marseille Univ, Marseille, France
Background/Purpose: Safety of denosumab, a fully human monoclonal antibody against RANKL developed for osteoporosis and prevention of fracture remains unclear in kidney transplanted patients. A…
Abstract Number: 1026 • 2017 ACR/ARHP Annual Meeting
Gene Expression Analysis Reveals Common Pathways of Tissue Pathogenesis in Lupus Organ Involvement
Amrie Grammer¹, Sarah Heuer¹, Robert Robl¹, Adam Labonte¹, Prathyusha Bachali¹, Sushma Madamanchi¹ and Peter E. Lipsky², ¹AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Lupus is a prototypic autoimmune disease characterized by B cell hyperactivity, autoantibody formation and resultant tissue damage. The mechanisms underlying tissue pathology in lupus…
Abstract Number: 211 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Febuxostat in Advanced CKD Patients with Hyperuricemia
Yoon-Jeong Oh¹, Seung Min Jung¹, Sang-Won Lee², Yong-Beom Park² and Jason Jungsik Song², ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Dosing adjustments and increased risk of serious side effects of uric acid lowering agents in patients with reduced renal function lead to undercorrection of…
Abstract Number: 346 • 2016 ACR/ARHP Annual Meeting
Interest of Bone Texture Assessment By Trabecular Bone Score (TBS) in Kidney Transplants Recipients
Marie Aubé¹, Alain Daragon¹, Olivier Vittecoq², Dominique Bertrand³, Mathilde Lemoine³, Jean François Menard⁴ and Christopher Banse⁵, ¹Rheumatology, CHU Hôpitaux de Rouen, Rouen, France, ²Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ³Nephrology, CHU Hôpitaux de Rouen, Rouen, France, ⁴Biostatistics, Université de Rouen, Rouen, France, ⁵Rheumatology, Rouen University Hospital, Rouen, France
Background/Purpose: Osteoporosis in kidney transplant is complex and multifactorial. We studied the evolution of Trabecular Bone Score (TBS) and bone mineral density (BMD) in kidney…
Abstract Number: 352 • 2016 ACR/ARHP Annual Meeting
Can Lumbar Spine Bone Mineral Density Predict Readmission in Denosumab-Treated Chronic Kidney Disease Patients?
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., YC Chen, Kaohsiung County, Taiwan
Background/Purpose: This study investigated whether bone mineral density (BMD) affects readmission risk in patients with CKD who received denosumab therapy. Methods: All subjects underwent dual…
Abstract Number: 353 • 2016 ACR/ARHP Annual Meeting
Changes in Femoral Neck Bone Mineral Density Inverse Correlate with Egfr in Denosumab Treated Osteoporosis Patients? a Hospital-Based Analysis
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan., YC Chen, Kaohsiung County, Taiwan
Background/Purpose: This study investigated the effect of different severities of CKD on bone mineral density (BMD) in patients treated with denosumab. Methods: This study was…
Abstract Number: 912 • 2016 ACR/ARHP Annual Meeting
Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease
Gerald D. Levy^1,2, Craig Cheetham³, Nazia Rashid⁴ and Jiaxiao Shi³, ¹Internal Medicine/Rheumatology, Southern California Kaiser Permanente, Downey, CA, ²Rheumatology, Kaiser Permanente Southern California, Downey, CA, ³Research and Evaluation, Southern California Medical Group, Pasadena, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente, Downey, CA
Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease Levy G, Cheetham C, Shi J, Rashid N Background/Purpose: To determine if urate lowering…
Abstract Number: 1865 • 2016 ACR/ARHP Annual Meeting
Urinary Cell Adhesion Molecules As Markers of Renal Involvement in Systemic Sclerosis
Edward Stern¹, Voon H. Ong², Aine Burns³, Robert Unwin⁴ and Christopher Denton⁵, ¹UCL Division of Medicine, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Nephrology, Royal Free Hospital, London, United Kingdom, ⁴Nephrology, UCL Division of Medicine, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: Renal involvement in systemic sclerosis (SSc) includes scleroderma renal crisis as well as progressive organ fibrosis. Detection and management of these disease complications is…
Abstract Number: 3129 • 2016 ACR/ARHP Annual Meeting
The Pharmacokinetics of Oxypurinol in Patients Treated with Hemodialysis and Allopurinol
Matthew Doogue¹, Dan Wright², Nick Cross³, John Irvine³, Peter T. Chapman⁴, Murray Barclay⁵ and Lisa K. Stamp¹, ¹University of Otago, Christchurch, New Zealand, ²School of Pharmacy, University of Otago, Dunedin, New Zealand, ³Nephrology, Christchurch Hospital, Christchurch, New Zealand, ⁴Christchurch Hospital, Christchurch, New Zealand, ⁵Medicine, University of Otago, Christchurch, New Zealand
Background/Purpose: Allopurinol is recommended as a first-line pharmacologic urate-lowering therapy in gout. Oxypurinol, the active metabolite of allopurinol, is entirely cleared by the kidneys. Oxypurinol…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].